ReviewESMO open2025

Retreatment, rechallenge, and escalation with subsequent immune checkpoint inhibitor therapies across cancers after initial failure.

I P da Silva et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.